Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Titan Pharmaceuticals, Inc. (TTNP) had Income from Continuous Operations of $-0.69M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-0.69M |
|
-- |
|
-- |
|
$0.66M |
|
$-0.66M |
|
$-0.03M |
|
$-0.69M |
|
$-0.69M |
|
$-0.69M |
|
|
Income from Continuous Operations |
$-0.69M |
$-0.69M |
|
$-0.69M |
|
$-0.66M |
|
$-0.66M |
|
1.06M |
|
1.06M |
|
$-0.65 |
|
$-0.65 |
|
| Balance Sheet Financials | |
$3.05M |
|
-- |
|
-- |
|
$3.05M |
|
$0.26M |
|
-- |
|
-- |
|
$0.26M |
|
$2.79M |
|
$2.79M |
|
$2.79M |
|
1.33M |
|
| Cash Flow Statement Financials | |
$-1.55M |
|
-- |
|
$1.52M |
|
$2.83M |
|
$2.80M |
|
$-0.03M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.72% |
|
-24.71% |
|
-22.58% |
|
-24.71% |
|
$2.10 |
|
$-1.45 |
|
$-1.45 |
|